Figure 2.

Establishing a Renewable and Reproducible Source of hGPCs from hESCs for In Vitro Modeling of Direct Neuronal Conversion

(A) Schematic overview of the protocol for generating hESC-derived hGPCs, with an indication of the time frame used for cryopreservation.

(B) Bright-field images of the hESC-derived hGPCs cultures at different stages and before and after cryopreservation.

(C) GFAP/PDGFRα immunostaining of the hESC-derived hGPC cultures at different stages and before and 15 days after cryopreservation. Insets show close-up morphology of cells in the boxed areas.

(D) Percentage of CD140⁺ cells within the cultures before and after cryopreservation as determined by flow cytometry.

(E and F) TH⁺/TAU⁺ cells (E) and NEUN⁺ cells (F) 3 weeks after activation of the transgenes ALN + shREST in hESC-derived hGPCs.

The proportions of CD140⁺ cells in Figure 2D were compared using a paired two-tailed t test; ^∗p < 0.05 (p = 0.0327). Scale bars: 100 μm. See also Figures S2 and S3.